Literature DB >> 2364845

Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.

M B Kimmey1, G W Elmer, C M Surawicz, L V McFarland.   

Abstract

A patient with six documented episodes of recurrent Clostridium difficile colitis over an eight-month period is described. Relapses of colitis occurred despite treatment with vancomycin, metronidazole, bacitracin, and cholestyramine. Each recurrence appeared to begin successively closer to the end of the previous course of treatment. Four episodes were sufficiently severe to require hospitalization for rehydration. Saccharomyces boulardii, a nonpathogenic yeast, was begun prior to discontinuing vancomycin therapy for the last recurrence and was continued for three months. Serial stool cultures and assays for C. difficile showed persistence of the organism but rapid reduction of high titers of cytotoxin. No further recurrences of diarrhea or colitis were encountered while the patient was taking Saccharomyces boulardii and for 18 months of follow-up after the yeast was discontinued.

Entities:  

Mesh:

Year:  1990        PMID: 2364845     DOI: 10.1007/bf01536805

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Evaluation of a commercially available latex immunoagglutination test kit for detection of Clostridium difficile D-1 toxin.

Authors:  S Kamiya; S Nakamura; K Yamakawa; S Nishida
Journal:  Microbiol Immunol       Date:  1986       Impact factor: 1.955

2.  Nosocomial acquisition of Clostridium difficile infection.

Authors:  L V McFarland; M E Mulligan; R Y Kwok; W E Stamm
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245

3.  Disposition kinetics of Saccharomyces boulardii in man and rat.

Authors:  H Blehaut; J Massot; G W Elmer; R H Levy
Journal:  Biopharm Drug Dispos       Date:  1989 Jul-Aug       Impact factor: 1.627

4.  Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG.

Authors:  S L Gorbach; T W Chang; B Goldin
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

5.  Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism.

Authors:  S Johnson; A Adelmann; C R Clabots; L R Peterson; D N Gerding
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

6.  Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy.

Authors:  B A Walters; R Roberts; R Stafford; E Seneviratne
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

7.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

8.  Treatment of recurrent antibiotic-associated pseudomembranous colitis.

Authors:  F J Tedesco
Journal:  Am J Gastroenterol       Date:  1982-04       Impact factor: 10.864

9.  Comparison of Minitek Anaerobe II, API An-Ident, and RapID ANA systems for identification of Clostridium difficile.

Authors:  G Bate
Journal:  Am J Clin Pathol       Date:  1986-06       Impact factor: 2.493

10.  Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters.

Authors:  G W Elmer; L V McFarland
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

View more
  11 in total

1.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

2.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

Authors:  D M Lyerly; E F Bostwick; S B Binion; T D Wilkins
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

3.  Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.

Authors:  A Qamar; S Aboudola; M Warny; P Michetti; C Pothoulakis; J T LaMont; C P Kelly
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  Saccharomyces boulardii in maintenance treatment of Crohn's disease.

Authors:  M Guslandi; G Mezzi; M Sorghi; P A Testoni
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

5.  Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans.

Authors:  Anna M Buchner; Amnon Sonnenberg
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

6.  Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers.

Authors:  S M Klein; G W Elmer; L V McFarland; C M Surawicz; R H Levy
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

7.  Treatment of Clostridium difficile Infection.

Authors:  John R. Stroehlein
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

Review 8.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

9.  Probiotics for the treatment of Clostridium difficile associated disease.

Authors:  Leo R Fitzpatrick
Journal:  World J Gastrointest Pathophysiol       Date:  2013-08-15

10.  Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice.

Authors:  Leo R Fitzpatrick; Jeffrey S Small; Wallace H Greene; Kelly D Karpa; Sean Farmer; David Keller
Journal:  Gut Pathog       Date:  2012-10-22       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.